Author

Karen C. Wolff

Scripps Research Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Organism:human· 2 Research Focus:host-pathogen & immune response· 1 Assay:structural biology· 1

Frequent Co-Authors

Laura RivaiD· 4 shared Amal Gebara-LambiD· 3 shared Arnab K. ChatterjeeiD· 3 shared Case W. McNamaraiD· 3 shared Malina A. BakowskiiD· 3 shared Melanie G. KirkpatrickiD· 3 shared Alireza Rahimi· 2 shared Anil K. Sen GuptaiD· 2 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersPharmacology & Toxicology

Laura RivaORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Pan-Coronavirus Protease Engagement and Differentiated Pharmacology of Antiviral Candidate CMX990

N. G. R. Dayan Elshan, Karen C. Wolff, Laura Riva, Malina A. Bakowski, Simeon Babarinde, Anshul Chaudhary, Mark Zeller, Ashley K. Woods, Gennadii A. Grabovyi, Katy B. Wilson, Rebecca A. Leonard, Briana Lynn McGovern, Jared Benjamin, Isidora D. Suazo, Mary Gordon, , Arnab K. Chatterjee

This study evaluates CMX990, a coronavirus Mpro inhibitor, showing broad antiviral activity against multiple coronaviruses and superior pharmacologic properties compared to existing inhibitors.

bioRxiv · Oct 1, 2026 · PreprintPharmacology & Toxicology

Orally Bioavailable SARS-CoV-2 Protease Inhibitors Bearing a Hydroxymethyl Ketone Warhead

N. G. R. Dayan Elshan, Karen C. Wolff, Frank O. Weiss, Sourav Ghorai, Gennadii A. Grabovyi, Katy Wilson, Laura Riva, Ashley K. Woods, James R. Pedroarena, Armen Nazarian, Yuyin Liu, Wrickban Mazumdar, Lirui Song, Neechi Okwor, Jacqueline Malvin, , Arnab K. Chatterjee

This paper describes the development of orally bioavailable SARS-CoV-2 protease inhibitors with a hydroxymethyl ketone warhead, showing improved potency and bioavailability compared to previous compounds.

Viruses · Jul 26, 2026Peer-reviewedPharmacology & Toxicology

Substrate and target selectivity of 4'-fluoroadenosine against viral and host polymerases

Simon M. Walker, Arlo J. Loutan, Egor P. Tchesnokov, Dana Kocíncová, Calvin J. Gordon, Ruby A. Escobedo, Nathaniel D. Jackson, Olivia A. Vogel, Kimberly M. Morsheimer, Suncheol Park, Anant Gharpure, Ixchel Urbano, Mina L. Heacock, Zhong Chen, Khushboo Pathak, , Matthias Götte

This study investigates the antiviral activity and mechanism of 4'-fluoroadenosine against viral and host polymerases, showing broad-spectrum inhibition and potential for drug development.

Journal of Biological Chemistry · Jul 6, 2026Peer-reviewedMicrobiology

High Throughput Screening with a Primary Human Mucociliary Airway Model Identifies a Small Molecule with Anti-SARS-CoV-2 Activity

Chandani Sen, Tammy M. Rickabaugh, Arjit Vijey Jeyachandran, Constance Yuen, Maisam Ghannam, Abdo Durra, Adam W. Aziz, Kristen Castillo, Gustavo Garcia, Arunima Purkayastha, Brandon Han, Felix W. Boulton, Eugene L. Piatnitski Chekler, Robert G. Garces, Karen C. Wolff, , Brigitte N. Gomperts

This study uses a primary human stem cell-based airway model to screen 2100 compounds and identifies a small molecule effective against SARS-CoV-2 and its Omicron variant.

Respiratory Research · Jan 16, 2025Peer-reviewedCell Biology